Phase II study of liposomal vincristine (lipoV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Thomas, DA
Sarris, A
O'Brien, S
Cortes, J
Giles, FJ
Faderl, S
Keating, MJ
Burge, C
Cabanillas, F
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[3] Inex Pharmaceut Corp, Burnaby, BC, Canada
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4269
引用
收藏
页码：238B / 238B
页数：1
相关论文
共 50 条
  • [21] Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients
    Oriol, Albert
    ACTA HAEMATOLOGICA, 2015, 133 (01) : 89 - 90
  • [22] A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia
    Rosen, PJ
    Rankin, C
    Head, DR
    Boldt, DH
    Luthardt, FW
    Norwood, T
    Pugh, RP
    Karanes, C
    Appelbaum, FR
    LEUKEMIA RESEARCH, 2000, 24 (03) : 183 - 187
  • [23] Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
    Sasaki, Koji
    Jabbour, Elias
    O'Brien, Susan
    Thomas, Deborah
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    Short, Nicholas
    Issa, Ghayas
    Gachimova, Evguenia
    Garris, Rebecca
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S266 - S266
  • [24] A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
    Wartman, Lukas D.
    Fiala, Mark A.
    Hawkins, Emily
    Fletcher, Theresa
    Allen, Melissa
    Cashen, Amanda F.
    DiPersio, John F.
    Jacoby, Meagan
    Stockerl-Goldstein, Keith E.
    Pusic, Iskra
    Uy, Geoffrey L.
    Westervelt, Peter
    Vij, Ravi
    BLOOD, 2014, 124 (21)
  • [25] A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia
    Wartman, Lukas D.
    Fiala, Mark A.
    Fletcher, Theresa
    Hawkins, Emily R.
    Cashen, Amanda
    DiPersio, John F.
    Jacoby, Meagan A.
    Stockerl-Goldstein, Keith E.
    Pusic, Iskra
    Uy, Geoffrey L.
    Westervelt, Peter
    Vij, Ravi
    LEUKEMIA & LYMPHOMA, 2016, 57 (03) : 728 - 730
  • [26] Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia
    O G Ottmann
    R A Larson
    H M Kantarjian
    P D le Coutre
    M Baccarani
    A Hochhaus
    D W Kim
    X Fan
    S Novick
    F J Giles
    Leukemia, 2013, 27 : 1411 - 1413
  • [27] Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
    Raj, Trisha A. Soosay
    Smith, Amanda M.
    Moore, Andrew S.
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2013, 8 : 4361 - 4369
  • [28] Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Kobayashi, Yukio
    Zimmerman, Zachary F.
    Oh, Iekuni
    Maeda, Yoshinobu
    Minami, Hironobu
    Miyamoto, Toshihiro
    Sakura, Toru
    Iida, Hiroatsu
    Chen, Yuqi
    Kiyoi, Hitoshi
    BLOOD, 2018, 132
  • [29] Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo™) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Stock, Wendy
    Heffner, Leonard
    Hirabayashi, Sue
    Lu, Biao
    Deitcher, Steven R.
    O'Brien, Susan
    BLOOD, 2008, 112 (11) : 1008 - 1008
  • [30] Methotrexate, vincristine, PEG-asparaginase and prednisone (MOAP) for patients (pts) with refractory or relapsed acute lymphoblastic leukemia (ALL).
    Cortes, J
    Kantarjian, H
    OBrien, S
    Andreeff, M
    Estey, E
    Keating, M
    BLOOD, 1997, 90 (10) : 3816 - 3816
12345